Gary Ulaner, MD, PhD, FACNM


A Look Into The Future of PSMA-Targeted Therapies in Prostate Cancer

December 12, 2022

Panelists review the recent FDA approval of the PSMA-targeted therapy Lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer and discuss additional settings in which it, and other PSMA-targeted treatments, might be used in the future.